India rejects teneligliptin salts patent
This article was originally published in Scrip
Executive Summary
India has rejected Mitsubishi Tanabe's patent application relating to certain salts of teneligliptin, the dipeptidyl peptidase-4 (DPP-4) inhibitor currently in the news after the arrival of a cut-price generic version on the domestic market.
You may also be interested in...
Mitsubishi Takes Teneligliptin Patent Appeal To Indian Court
Japan's Mitsubishi Tanabe has moved a court against Indian patent authorities in a case concerning its patent application relating to certain salts of teneligliptin. The move has set the cat among the pigeons in the Indian market, where cut price versions of the diabetes drug have made strong gains over the recent past, though it's still unclear if the salt patent may have a bearing on these.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet